Purpose In oncology patients, hospital malnutrition is associated with a greater risk of morbidity and mortality. The objective of this study was to determine the prevalence of nutritional risk and the clinical and economic consequences of hospital malnutrition in oncology patients hospitalised in Spanish centres. Methods This was an observational, cross-sectional, multicentre study. The prevalence of nutritional risk was determined using the Nutrition Risk Screening Results Four hundred one oncology patients were included; 33.9 % (136/401) were at nutritional risk (NRS ® -2002 ≥ 3) at admission and 36.4 % (135/371) at discharge. On average, patients at nutritional risk were more elderly and had lower weights, body mass indices and arm and calf circumferences, as well as lower serum albumin levels than patients not at risk. Mean duration of hospitalisation and healthcare costs were greater in patients at nutritional risk at discharge (12.1 days; 95 % confidence interval (CI) 10.83-13.39) than in wellnourished patients (8.6 days; 95 % CI 7.86-9.40). Only a third of the patients at risk of malnutrition at discharge had received any kind of nutritional support. Conclusions This study shows that hospital malnutrition is a prevalent and undertreated condition in oncology patients that is associated with longer hospital stays and increased healthcare costs.
Introduction
Hospital malnutrition (HM) is a prevalent condition with major clinical and economic consequences [1, 2] . In oncology patients, HM has been associated with a greater risk of complications [3, 4] , longer hospital stays [5] , poorer tolerance and response to treatments [6] , lower survival [7, 8] and a significant decline in patients' quality of life [9] [10] [11] [12] .
The aetiology of malnutrition in cancer patients is complex. Some factors, such as the presence of metabolic disorders related to the neoplastic process, insufficient nutrient intake and a high incidence of adverse gastrointestinal effects including mucositis, diarrhoea and nausea have been related to alterations in the nutritional status of oncology patients [13, 14] . Cachexia, a metabolic process closely related to malnutrition and characterised by rapid weight loss due to depletion of fatty tissue and muscle mass, affects 80 % of patients with advanced disease and is responsible for more than 30 % of the deaths of cancer patients [15] .
Although nutritional status generally worsens as the disease progresses and with the administration of cytotoxic treatments [16] [17] [18] [19] , malnutrition can appear at any time during the disease, even at diagnosis [20] . It is not in vain that anorexia and weight loss with no apparent cause are reasons to suspect the presence of a tumour. Moreover, the presence of nutritional deficits in the initial stages of the disease can affect the tolerability of chemotherapy [21] .
In a study conducted in 3047 patients with different types of tumour, between 31 and 87 % of the patients experienced weight loss before receiving chemotherapy [22] . In another study in patients with gastrointestinal tumours, 70 % of patients with tumours in the lower intestinal tract, 78 % of patients with oesophageal or stomach cancer and 87 % of patients with pancreatic tumours presented weight loss at diagnosis [20] . In a study conducted in Spain in patients with metastatic or advanced cancer in which 60 % of them were receiving chemotherapy or radiotherapy, malnutrition prevalence rates were over 50 % according to the Patient-Generated Subjective Global Assessment (PG-SGA) [23] .
Despite the importance of malnutrition for the clinical evolution of oncology patients, there is not yet a universally accepted standard method for evaluating malnutrition in such patients. In hospitalised patients, the European Society for Clinical Nutrition and Metabolism (ESPEN) recommends the use of the NRS ® -2002, a tool that includes diagnosis of cancer as a risk factor for malnutrition [24] .
The objectives of this study are to determine the prevalence of nutritional risk in oncology patients hospitalised in Spain using the NRS ® -2002 tool, analyse the clinical characteristics of these patients at admission and discharge, and evaluate the clinical and economic consequences of malnutrition in this population.
Materials and methods

Study design
This study evaluated the prevalence of nutritional risk in the subgroup of patients diagnosed with oncological disease in the PREDyCES ® study. The PREDyCES ® study was an observational, cross-sectional, multicentre study conducted in sites all over Spain from April to September 2009. The design, inclusion and exclusion criteria of the PREDyCES ® study have been described in detail in previous publications [25, 26] .
Variables
Sociodemographic data, anthropometric measurements (weight, height, arm and calf circumference), and anthropometric measurements and biochemical parameters were collected at admission and discharge.
The nutritional status was evaluated by the NRS ® -2002 tool at admission (in the first 48 h after admission) and at discharge (or 28 days after admission if duration of hospitalisation was ≥28 days). The prevalence of nutritional risk (percentage of oncology patients included in the PREDyCES ® study with an NRS ® -2002 score ≥3) was determined at both admission and discharge for all the oncology patients and for subgroups of oncology patients according to tumour, sex and age.
Sample size and statistical analysis
The sample size was determined by the number of oncology patients who participated in the PREDyCES ® study. In the PREDyCES ® study, the sample size was calculated from malnutrition prevalence data in previous studies conducted in Spain [26] .
A descriptive data analysis was performed. The mean, standard deviation and 95 % confidence intervals (CIs) for the mean were calculated for the continuous variables. Relative and absolute frequencies were calculated for the categorical variables.
The differences between the anthropometric measurements at admission and discharge were evaluated by the Wilcoxon signed-rank test. The differences in the prevalence of nutritional risk according to age (<70 vs. ≥70), sex and type of admission (scheduled or urgent) were evaluated by Fisher's exact tests. The differences in mean age, biochemical parameters and anthropometric measurements between patients with and without malnutrition risk were evaluated by t tests. In all the analyses, the statistical significance threshold was set at p < 0.05.
Severe weight loss was defined as reduction of more than 2, 3, 4 or 5 % of patients' initial weight during hospital stays of up to 10, 20, 30 days or more than 30 days, respectively.
Length of in-hospital stay (LOS) was calculated by the patients' dates of admission and discharge. Hospitalisation costs were calculated from the days of hospitalisation and the average cost per day of admission provided by the Ministry of Health and Consumer Affairs.
Statistical analysis was performed with SPSS® 15.0 for Windows (SPSS Inc., Illinois, United States).
Ethical considerations
The PREDyCES ® study was approved by the Hospital Universitario La Paz ethics committee and conducted following the principles of the Declaration of Helsinki and the 1996 International Conference on Harmonisation Good Clinical Practice standards. All the patients granted their informed consent in writing to participate in the PREDyCES ® study. Approximately one third of the patients (39.2 %) were 70 years of age or older at admission and the mean age ± standard deviation (SD) was 64.6 ± 14 years. Two thirds (61.6 %) of the patients were men.
Patients had a mean body weight of 66.89 ± 16.13 kg at admission and 65.38 ± 15.40 kg at discharge, with a significant mean difference of −1.83 kg between weight at admission and discharge (p < 0.001). Patients who were ≥70 years old exhibited a mean weight loss of 2.11 kg (p < 0.001) ( Table 1) .
Mean body mass index (BMI) was 24.70 ± 5.81 kg/m 2 at admission and 24.17 ± 5.65 kg/m 2 at discharge, with a significant mean difference of −0.67 kg/m 2 between BMI at admission and discharge (p < 0.001). Patients ≥70 years old had a mean reduction in BMI of 0.71 kg/m 2 (p = 0.001) ( Table 2) The departments with the greatest prevalence of nutritional risk were oncology (50.0 %), haematology (46.2 %), internal medicine (40.4 %), otorhinolaryngology (36.8 %) and general and gastrointestinal surgery (36.7 %). All the patients aged ≥70 years admitted to respiratory, neurology and oncology departments and half or more than half of the patients aged ≥70 years admitted to haematology (87.5 %), general and gastrointestinal surgery (57.4 %) and gastroenterology (50.0 %) were at nutritional risk at admission.
When the results were analysed according to tumour location, the prevalence of nutritional risk at admission was In comparison with the patients not at risk, the patients at risk of malnutrition at admission presented an older mean age, lower weight, BMI and arm and calf circumference and lower serum albumin levels ( Table 3 ).
The mean LOS among patients at nutritional risk at discharge was 12.1 days (95 % CI 10.83-13.39), while among well-nourished patients, it was 8.6 days (95 % CI 7.86-9.40). Healthcare costs were also significantly higher in patients at risk (€8596; 95 % CI €7605.53-9585.98) compared to patients not at risk (€6652; 95 % CI €5961.79-7643.70) (p = 0.001) (Fig. 1) .
66.7 % of the oncology patients at nutritional risk at discharge had not received nutritional support during hospitalisation. This percentage increased to 73.0 % in the group of patients 70 years of age or older (Fig. 2) . 
Discussion
In Spain, the prevalence of HM has been evaluated by the NRS ® -2002 tool in four studies [25, [27] [28] [29] . The prevalence results obtained in these studies ranged from 24 % [25] to 62 % [28] . In the PREDyCES ® study [25] , the diagnosis of malignant neoplasms was identified as a risk factor for the development of malnutrition (OR 2.89 [2.14-3.90]; p < 0.001).
This study, conceived as a substudy of the PREDyCES This study shows that hospitalised oncology patients, especially older oncology patients, are at a high risk of malnutrition. Specifically, more than 30 % of oncology patients, and more than 40 % of oncology patients who were ≥70 years old were at risk of malnutrition at admission.
Note that approximately half of the patients admitted to oncology and haematology departments were at risk of malnutrition at admission, showing that the risk of malnutrition is prevalent in both patients with solid tumours and patients with haematological neoplasms.
In patients aged ≥70 years, the prevalence of nutritional risk at admission to respiratory, neurology, oncology and haematology departments was 100 % or close to 100 %, meaning that virtually all elderly oncology patients admitted to these departments are at risk of malnutrition.
Our results are consistent with those in studies that evaluated the prevalence of nutritional risk in oncology patients using the NRS ® -2002 in Turkey [30] , Italy [31] and Romania [32] , which also detected prevalences close to 30 %. However, the prevalence detected in our study is lower than that found in other studies conducted in Mexico [33] , the Czech Republic [34] and Norway [35] . One possible explanation lies in the existence of differences in the baseline characteristics of the populations, including differences in the distribution by sex and age or in tumour location and stage. The increased prevalence of risk of malnutrition together with the reduction in mean body weight and BMI, together with the gradual weight loss during hospitalisation suggests that the nutritional status of oncology patients worsens during hospitalisation. In fact, in elderly patients, the prevalence of nutritional risk at discharge was 12 % higher than at admission (50 vs. 38 %).
The tendency for nutritional status to decline during hospitalisation was particularly significant in patients with haematological neoplasms, in which the prevalence of nutritional risk was of 36.8 % at admission and 51.6 % at discharge, and in patients with tumours of the lower gastrointestinal tract (39.1 % at admission vs. 46.3 % at discharge) and of the upper gastrointestinal tract (47.4 % at admission vs. 50.0 % at discharge).
Despite the importance of nutritional status in the evolution and quality of life of oncology patients [5, 11] , and the growing evidence of the efficiency of taking steps to correct hospital malnutrition [36] , only a third of the patients who were at nutritional risk at discharge had received some kind of nutritional support during hospitalisation. This contrasts with the recommendations regarding enteral and parenteral nutrition in oncology patients issued by ESPEN [37, 38] and by the Spanish Society for Parenteral and Enteral Nutrition (SENPE), the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Medical Radiology (SEOR) [39] .
Another point to stress is that, although BMI values were lower in patients at risk than in patients not at risk, both groups had BMI values close to normality both at admission and at discharge, supporting the idea that BMI alone is not a sufficient indicator of nutritional status [40, 41] .
In our study, the presence of nutritional risk was associated with significantly longer hospitalisation and a significant increase in cost, which is consistent with the results of other studies in which malnutrition was associated with longer hospitalisation, poorer quality of life, greater risk of complications and reduced tolerance and response to treatments [3] [4] [5] [6] [42] [43] [44] .
Implementing strategies to detect malnutrition early in all stages of the disease is essential for taking measures to help to prevent its fatal consequences [13] and improving patients' quality of life [45] [46] [47] .
The most significant limitation of this study is that it is a subanalysis of a study that included both oncology patients and non-oncology patients, which has implications for both the sample size and the collected variables. On the one hand, the sample size was not calculated in order to estimate the prevalence or relation between nutritional risk and hospital stay in oncology patients; instead, it was determined by the number of patients who participated in the general study. On the other hand, the reduced number of patients with each type of tumour and the lack of information regarding tumour stage limits the conclusions that can be reached from the study. Another limitation is that the cost was calculated based on duration of hospitalisation, without considering incidence or cost of complications. In future studies, it will be interesting to evaluate the prevalence of nutritional risk in a larger number of oncology patients, stratified according to type of tumour to determine incidence of complications, mortality and response to treatments, and to characterise the costs associated with HM in detail. Notwithstanding its limitations, this study provides valuable information regarding the prevalence and burden of malnutrition in a set of oncology patients representative of routine clinical practice in Spain.
In conclusion, this study shows that nutritional risk is a prevalent condition in hospitalised oncology patients. In these patients, nutritional risk is associated with extended hospitalisation and increased healthcare costs. The results of this study also suggest that the nutritional status of oncology patients worsens during hospitalisation. 
